- Home
- LSTA vs SLGL Comparison
LSTA vs SLGL Comparison
Compare LSTA & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- SLGL
- Stock Information
- Founded
- LSTA 1980
- SLGL 1997
- Country
- LSTA United States
- SLGL Israel
- Employees
- LSTA N/A
- SLGL N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- LSTA Health Care
- SLGL Health Care
- Exchange
- LSTA Nasdaq
- SLGL Nasdaq
- Market Cap
- LSTA 20.0M
- SLGL 21.1M
- IPO Year
- LSTA N/A
- SLGL 2018
- Fundamental
- Price
- LSTA $2.69
- SLGL $7.24
- Analyst Decision
- LSTA Strong Buy
- SLGL Buy
- Analyst Count
- LSTA 1
- SLGL 1
- Target Price
- LSTA $15.00
- SLGL $40.00
- AVG Volume (30 Days)
- LSTA 15.4K
- SLGL 13.2K
- Earning Date
- LSTA 05-08-2025
- SLGL 05-23-2025
- Dividend Yield
- LSTA N/A
- SLGL N/A
- EPS Growth
- LSTA N/A
- SLGL N/A
- EPS
- LSTA N/A
- SLGL N/A
- Revenue
- LSTA $1,000,000.00
- SLGL $12,103,000.00
- Revenue This Year
- LSTA N/A
- SLGL N/A
- Revenue Next Year
- LSTA N/A
- SLGL $31.17
- P/E Ratio
- LSTA N/A
- SLGL N/A
- Revenue Growth
- LSTA N/A
- SLGL 603.66
- 52 Week Low
- LSTA $1.87
- SLGL $3.34
- 52 Week High
- LSTA $4.20
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- LSTA 57.86
- SLGL 50.26
- Support Level
- LSTA $2.59
- SLGL $7.15
- Resistance Level
- LSTA $2.80
- SLGL $7.45
- Average True Range (ATR)
- LSTA 0.19
- SLGL 0.32
- MACD
- LSTA 0.00
- SLGL -0.10
- Stochastic Oscillator
- LSTA 59.09
- SLGL 31.36
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.